期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 10, 期 2, 页码 207-217出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.875856
关键词
IL-2; IL-2 receptor; immune response; tumor immunotherapy; tumor microenvironment
类别
资金
- National Institutes of Health [AI07285]
- University of Rochester CTSA from the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1 TR000042]
Interleukin-2 (IL-2) is a cytokine with pleiotropic effects on the immune system. Systemic IL-2 treatment has produced durable responses in melanoma and renal cancer patients, but unfortunately this is effective only in a fraction of patients. Moreover, IL-2 treatment also engenders serious side effects, which limit its clinical utility. It is now appreciated that IL-2 not only stimulates NK and effector T cells but also has a critical role in the generation and maintenance of regulatory T cells, which act to dampen immune responses. Thus, successful immunotherapy of cancers using IL-2 has to address two fundamentally important issues: (1) how to limit side effects yet be active where it is needed, and (2) how to preferentially activate effector T cells while limiting the stimulation of Tregs. Strategies are now being developed to address these critical obstacles that may lead to a renaissance of IL-2 therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据